Your session is about to expire
← Back to Search
Study Summary
This trial tests how safe and tolerable a new cancer treatment is for adults with certain types of tumors.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I haven't had cancer in the last 3 years, except for specific minor cases.I have not taken drugs targeting the PI3K-AKT-mTOR pathway, except if I have breast cancer.I haven't had cancer treatment before starting this trial.I have a history of diabetes.I have not had a recent heart attack or severe heart failure.I can provide a sample of my tumor for PIK3CA mutation testing.I am 18 years old or older.My cancer has a PIK3CA mutation or amplification.I am fully active or restricted in physically strenuous activity but can do light work.My blood, liver, and kidney tests are normal.I have active cancer spread to my brain or spinal cord.I have been diagnosed with Cushing syndrome.My cancer is advanced and cannot be cured, including specific types like colorectal, lung, or breast cancer.
- Group 1: TOS-358 Single Agent Arm
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has the administration given its sanction to TOS-358 Single Agent Arm?
"This Phase 1 clinical trial has not accumulated substantial evidence of safety or efficacy, thus it was rated a 1 on our scale."
What is the limit of volunteers taking part in this experiment?
"Indeed, the clinicaltrials.gov page reflects that this trial is presently seeking participants. This research was initially published on February 15th 2023 and updated most recently on March 10th 2023 with a total of 241 patient enrolment at 1 site."
Are there still opportunities to partake in this investigation?
"Indeed, the information posted on clinicaltrials.gov attests that this specific medical trial is currently accepting patients. Initially advertised on February 15th 2023, it has been updated most recently in March 10th 2023."
Share this study with friends
Copy Link
Messenger